Shuttle Pharmaceuticals Completes Manufacturing Of Active Pharmaceutical Ingredient For Use In Clinical Trial
Portfolio Pulse from Happy Mohamed
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) announced that TCG GreenChem has completed the initial manufacturing of the active pharmaceutical ingredient (API) of Ropidoxuridine for use in the company's upcoming Phase II clinical trial in brain cancer patients undergoing radiation therapy. The company's request for a Type B pre-IND meeting with the FDA for guidance on the proposed Phase II clinical trial has been approved, with responses expected by September 18, 2023. The company aims to commence its Phase II clinical study in the fourth quarter of 2023.
August 04, 2023 | 1:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Shuttle Pharmaceuticals' successful manufacturing of the API for its upcoming clinical trial and the FDA's approval of a pre-IND meeting for trial guidance are positive developments. These events could potentially boost investor confidence in the company's progress and timeline.
The successful manufacturing of the API is a crucial step towards the commencement of the clinical trial. The FDA's approval of a pre-IND meeting indicates regulatory progress and provides guidance for the upcoming trial. Both events are likely to be viewed positively by investors and could potentially impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100